Peter Slasor

Intramuscular Interferon Beta-1A Therapy Initiated during a First Demyelinating Event in Multiple Sclerosis

Roy W. Beck, Jack H. Simon, R. Phillip Kinkel et al. · New England Journal of Medicine · 2000 · 1.5K citations · Full text

Life Sciences, Neurology, Pharmacotherapy +10

Study of Intraventricular Cerliponase Alfa for CLN2 Disease

Angela Schulz, Temitayo Ajayi, Nicola Specchio et al. · New England Journal of Medicine · 2018 · 483 citations

Life Sciences, Neurology, Neuroscience +9

Efficacy and safety of enzyme replacement therapy with BMN 110 (elosulfase alfa) for Morquio A syndrome (mucopolysaccharidosis IVA): a phase 3 randomised placebo‐controlled study

Christian J. Hendriksz, Barbara K. Burton, Thomas R. Fleming et al. · Journal of Inherited Metabolic Disease · 2014 · 211 citations · Full text

Life Sciences, Pharmacology, Pharmacotherapy +12

The Morquio A Clinical Assessment Program: Baseline results illustrating progressive, multisystemic clinical impairments in Morquio A subjects

Paul Harmatz, Eugen Mengel, Roberto Giugliani et al. · Molecular Genetics and Metabolism · 2013 · 148 citations · Full text

Medicine, Physiology, Exercise Testing +15

Disease characteristics and progression in patients with late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease: an observational cohort study

Miriam Nickel, Alessandro Simonati, David Jacoby et al. · The Lancet Child & Adolescent Health · 2018 · 139 citations · Full text

Medicine, Neurology, Pediatrics +6